Pletal (Cilostazol) Drug Information: Overdosage and Contraindications

Pill Identifier Search

May 27, 2012

Pletal

Peripheral Vascular Disease »

What is peripheral vascular disease?

Peripheral vascular disease (PVD) refers to diseases of the blood vessels (arteries and veins) located outside the heart and brain. While there are many causes of peripheral vascular disease, doctors commonly use the term peripheral vascular disease to refer to peripheral artery disease (peripheral arterial disease, PAD), a condition that develops when the arteries that supply blood to the internal organs, arms, and legs become completely or partially blocked as a result of atherosclerosis.

What is atherosclerosis?

Atherosclerosis is a gradual process whereby hard cholesterol substances (plaques) are deposited in the walls of the arteries. Cholesterol plaques cause hardening of the artery walls and narrowing of the inner channel (lumen) of the artery. The atherosclerosis process begins early in life (as early as teens in some people). When atherosclerosis is mild an...

Read the Peripheral Vascular Disease article »

« Previous
1
2
3
4
5
6
7
8
9
10
11
12
13
Next »

Pletal User Reviews >>

Pletal

High Blood Pressure (Hypertension) Slideshow

Take the Salt Quiz!

Lowering Blood Pressure Exercise Tips Pictures

font size

OVERDOSE

Information on acute overdosage with Pletal (cilostazol) in humans is limited. The signs and symptoms of an acute overdose can be anticipated to be those of excessive pharmacologic effect: severe headache, diarrhea, hypotension, tachycardia, and possibly cardiac arrhythmias. The patient should be carefully observed and given supportive treatment. Since cilostazol is highly protein-bound, it is unlikely that it can be efficiently removed by hemodialysis or peritoneal dialysis. The oral LD₅₀ of cilostazol is > 5.0 g/kg in mice and rats and > 2.0 g/kg in dogs.

CONTRAINDICATIONS

Cilostazol and several of its metabolites are inhibitors of phosphodiesterase III. Several drugs with this pharmacologic effect have caused decreased survival compared to placebo in patients with class III-IV congestive heart failure. Pletal (cilostazol) is contraindicated in patients with congestive heart failure of any severity.

Pletal (cilostazol) is contraindicated in patients with haemostatic disorders or active pathologic bleeding, such as bleeding peptic ulcer and intracranial bleeding. Pletal (cilostazol) inhibits platelet aggregation in a reversible manner.

Pletal (cilostazol) is contraindicated in patients with known or suspected hypersensitivity to any of its components.

Last reviewed on RxList: 12/19/2007
This monograph has been modified to include the generic and brand name in many instances.